Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G

Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received b...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hiroya, Yamanaka, Takeharu, Sakai, Daisuke, Muro, Kei, Yamazaki, Kentaro, Nakata, Susumu, Kimura, Hiroyuki, Ruff, Paul, Kim, Tae Won, Peeters, Marc, Price, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/
https://www.ncbi.nlm.nih.gov/pubmed/32605298
http://dx.doi.org/10.3390/cancers12071715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/
https://www.ncbi.nlm.nih.gov/pubmed/32605298
http://dx.doi.org/10.3390/cancers12071715

Ejemplares similares